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A B S T R A C T   
TAR DNA-binding protein 43 (TDP-43) is a nuclear RNA/DNA binding protein involved in mRNA metabolism. 
Aberrant mislocalization to the cytoplasm and formation of phosphorylated/aggregated TDP-43 inclusions re-
mains the hallmark pathology in a spectrum of neurodegenerative diseases, including frontotemporal disorders 
and Alzheimer's disease. Eukaryotic Translation Initiation Factor 5A undergoes a unique post-translation mod-
ification of lysine to hypusine (K50), which determines eIF5A binding partners. We used a sodium arsenite- 
induced cellular stress model to investigate the role of hypusinated eIF5A (eIF5AHypK50) in governing TDP-43 
cytoplasmic mislocalization and accumulation in stress granule. Our proteomics and functional data provide 
evidence that eIF5A interacts with TDP-43 in a hypusine-dependent manner. Additionally, we showed that 
following stress TDP-43 interactions with eIF5AHypK50 were induced both in the cytoplasm and stress granules. 
Pharmacological reduction of hypusination or mutations of lysine residues within the hypusine loop decreased 
phosphorylated and insoluble TDP-43 levels. The proteomic and biochemical analysis also identified nuclear 
pore complex importins KPNA1/2, KPNB1, and RanGTP as interacting partners of eIF5AHypK50. These findings 
are the first to provide a novel pathway and potential therapeutic targets that require further investigation in 
models of TDP-43 proteinopathies.   
1. Introduction 
The TDP-43 proteinopathies include a spectrum of neurodegenera-
tive diseases where TDP-43 proteinopathy is present in 45% of cases of 
frontotemporal disorders (FTD)-TDP-43 subtype, and in 97% of patients 
with ALS with or without the cognitive impairment resembling FTD 
[1–3]. Recently, limbic-predominant age-related TDP-43 encephalo-
pathy (LATE) was described as a common condition in patients 80 years 
or older [4]. To date, TDP-43 proteinopathies are defined by a nuclear 
loss-of-function (LOF) and cytoplasm toxic gain-of-function (GOF), both 
of which lead to the formation of TDP-43 cytoplasmic inclusions in 
distinct brain regions in patients [2,4,5]. Nuclear TDP-43 plays an 
important role in the regulation of mRNA splicing, metabolism, and 
transport, however the etiology of these mechanisms is less understood 
[5–7]. The pathological phenotype of GOF is characterized by cyto-
plasmic inclusions of TDP-43 containing abnormal ubiquitylated, 
phosphorylated, insoluble TDP-43 as well as truncated 25–35 kDa TDP- 
43 C-terminal fragments (CTFs), followed by vast neurodegeneration 
[2]. Interestingly, TDP-43 is incorporated into cytoplasmic stress 
granules (SGs) that have been robustly observed in ALS, FTD brain, and 
animal models [8–12]. The mechanism of nuclear to SG trafficking of 
TDP-43 is unknown, but the idea of SGs as early-sites for TDP-43 pro-
tein aggregation has been proposed [11]. 
Eukaryotic Translation Initiation Factor 5A (eIF5A) is a small, acidic 
protein that is highly conserved throughout eukaryotes. eIF5A is the 
only cellular protein that utilizes spermidine to modify lysine 50 (K50) 
to hypusine residue [hypusine-N-(4-amino-2-hydroxybutyl) lysine] 
[13]. Hypusination occurs via two subsequentially enzymatic events 
executed by deoxyhypusine synthase (DHS, rate-limiting enzyme) and 
deoxyhypusine hydroxylase (DOHH) [14]. Sequence conservation is 
especially high within the “hypusine loop”, underscoring the im-
portance of this unusual protein modification throughout eukaryotic 
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evolution [15]. Early studies underlined the role of hypusinated eIF5A 
(eIF5AHypK50) in translation initiation process [13] and served as bases 
for discovering eIF5AHypK50 regulation of translation elongation of 
mRNAs involved in nuclear transport [16], mRNAs turnover [17], as 
well as posttranslational stress responses [18,19]. Further studies fur-
ther suggested that acetylation of lysine 47 and 68 within the “hypusine 
loop” presents another mechanisms for regulation of eIF5A cellular 
localization and activity [20–22]. 
Despite studies shedding light on the importance of hypusination in 
a range of biological processes, a significant gap exists regarding the 
role of eIF5AHypK50 in the neurobiological processes. A proteomic study 
demonstrated the first evidence of interactions of eIF5A with TDP-43 
identifying TDP-43 binding to the N-terminal of eIF5A in a hypusine- 
dependent manner [23]. Another study suggested the role of eIF5A in 
unfolded protein response (UPR) and chaperone expression [24], con-
ceivably implicating the eIF5A pathway in aberrantly folded protein 
responses. These findings provided the initial rationale for a plausible 
functional role of eIF5AHypK50 in neurodegenerative diseases. There-
fore, we aimed to investigate the role of eIF5AHypK50 in TDP-43 pro-
teinopathy focusing on the toxic GOF; cytoplasmic accumulation and 
aggregation, in several cellular models. We demonstrated that hypusi-
nated eIF5A governs the TDP-43 sequestration to the cytoplasm and 
accumulation into the stress granule (SG) in sodium arsenite (SA) in-
duced stress model. Importantly, we show that pharmacological in-
hibition of hypusination reduced TDP-43 cytoplasmic sequestration, 
phosphorylation, and aggregation as well as weakened the TDP-43 as-
sociations with eIF5AHypK50 in a tetracycline regulatable TDP-43 HeLa 
isogenic cellular model [3]. We report that a reduction in hypusine 
levels did not affect the overall de-novo protein synthesis in this cellular 
model, suggesting that hypusination regulates mainly eIF5A-TDP-43 
protein interactions. Lastly, proteomics and functional analysis identi-
fied nucleocytoplasmic transport cargo molecules; Ran, Karyopherin 
Subunit Alpha 1 and 2 (KPNA1/A2), and Karyopherin Subunit Beta 
1(KPNAB1), as complex molecules of eIF5AHypK50. Importantly, we 
demonstrated the advantages of the hypusination moiety as a novel 
therapeutic strategy against several features of the TDP-43 pathology in 
common dementias. 
2. Material and methods 
2.1. Cell culture and treatment 
HeLa LAP-wtTDP-43 cells (gifted by Dr. DW. Cleveland, Ludwig 
Institute for Cancer Research, University of California at San Diego, La 
Jolla, CA, USA) were grown as described [3]. Briefly, HeLa cells were 
maintained in OptiMEM media (Gibco by Life Technologies, CA, USA, # 
31985-070), 10% Heat-Inactivated Fetal Bovine Serum (HI-FBS, Sigma 
Aldrich, MO, USA, # F4135), and 1% Penicillin Streptomycin (Gibco by 
Life Technologies, CA, USA, # 15140122). LAP-wtTDP-43 cells were 
seeded in media containing 1 μg/mll tetracycline (tet, Sigma Aldrich, 
MO, USA, # 87128) for 24 h before treatment with 30 μM N1-guanyl- 
1,7-diaminoheptane for 72 h (GC7, Calbiochem, CA, USA, # 150333- 
69-0), followed by 0.5 mM sodium arsenite for 1 h (Ricca Chemical 
Company, TX, USA, # R7142000) (Supplementary Table 4). M17 cells 
were grown in OptiMEM, 10% HI-FBS, and 1% glutamax (Gibco by Life 
Technologies, CA, USA, # 35050061). 
For the mutagenesis experiments, eIF5A and K47/50R-eIF5A plas-
mids (generously gifted from Dr. MH Park, Oral, and Pharyngeal Cancer 
Branch, National Institute of Dental and Craniofacial Research, 
National Institutes of Health, Bethesda, MD, USA) were transfected into 
Hek293T cells. Cells were grown to 70% confluency in DMEM media 
(Gibco by Life Technologies, CA, USA, # 11965092) supplemented with 
10% Heat-Inactivated Fetal Bovine Serum (HI-FBS, Sigma Aldrich, MO, 
USA, # F4135) and 1% Penicillin Streptomycin (Gibco by Life 
Technologies, CA, USA, # 15140122). DMEM media was replaced with 
serum-deprived OptiMEM media (Gibco by Life Technologies, CA, USA, 
# 31985-070) and incubated at 37 °C for 20 min. The transfection re-
action was performed as recommended by the manufacturer (Invitrogen 
by Thermo Fisher Scientific, USA, # 11668-019). Briefly, 1μg of 
plasmid was mixed in a 1:1.5 ratio with Lipofectamin™ 2000 
Transfection Reagent in OptiMEM media and incubated at room tem-
perature for 20 min before treatment. OptiMEM media was changed to 
complete DMEM media 7 h later. Cells were harvested 72 h post- 
transfection and prepared for Western blot. 
2.2. AlamarBlue cell viability assay 
HeLa cells were grown in 96-well plate at a maximum density of 
100, 000 cells/well. 10 μl AlamarBlue (1: 10 dilution, # BUF012A, 
BioRad, CA, US) was added to each well and incubated for 1–4 h at 
37 °C (pH 6.8–7.4). The fluorescence intensity was measured using 
BioTek Cytation 5.0 plate reader (530-560 nm) to measure cell re-
spiration as an indicator for proliferation. Data are normalized to 
control and presented as percent change. 
2.3. Site-directed mutagenesis 
Site-directed mutagenesis was performed using QuickChange Site- 
Directed Mutagenesis kit (# 200518) on plasmid pCEFLGFP eIF5A at 
residue 47 and 50 Lysine (K) to Arginine (R). Mutation was introduced 
using the primers for eIF5AK47R_Fw (5′-gag atg tct act tcg agg act ggc 
aag cac ggc-3′), eIF5AK47R_Rv (5′-gcc gtg ctt gcc agt cct cga agt aga cat 
ctc-3′), eIF5AK50R_Fw’(5′-act tcg aag act ggc agg cac ggc cac gcc aag- 
3′) and eIF5AK50R_Rv’(5′-ctt ggc gtg gcc gtg cct gcc agt ctt cga agt’-3′) 
following the manufacturer's directions. Plasmids were sequenced by 
Eurofins (Louisville, KY, USA) to confirm mutations at K47/K50 re-
sidues. 
2.4. Immunoprecipitation 
Immunoprecipitation (IP) assay was performed as described else-
where [25] with slight modifications. Briefly, LAP-wtTDP-43 cells were 
harvested and lysed in Co-IP Radioimmunoprecipitation assay buffer 
according to the manufacturer's descriptions (Pierce, MA, USA, # 
20338). 10 μg protein was used as input while the remaining lysate was 
precleared at 4 °C with Protein A Trisacryl Resin beads (Pierce, MA, 
USA, # 20338) and conjugated to either TDP-43 (Proteintech, IL, USA, 
# 12892-1-AP) or isotype control IgG antibody (Thermo Fisher Scien-
tific, MA, USA, # 31887). After antibody incubation, beads were rinsed 
3 x with cold, sterile PBS, and resuspended in 50 μl of resuspension 
buffer (50 mM Tris HCl pH 7.4, 5 mM EDTA, 10 mM DTT, and 1% SDS) 
and denatured using 5 X SDS loading buffer. Input and IP samples were 
analyzed on a Western blot and probed with the following antibodies 
(Supplementary Table 4): eIF5AHyp-K50 (21st Century Biochemicals, 
MA, USA), TDP-43 (Sigma Aldrich, MO, USA, # WH0023435M1), and 
TIAIA-1 (Santa Cruz Biotechnology, TX, USA # sc-1751). The inputs 
were probed with either GAPDH (Proteintech, IL, USA, # HRP-60004) 
or β-Actin (Sigma Aldrich, MO, USA, A5441). IP was performed in 
triplicates and verified in four independent experimental set-ups. 
2.5. Mass spectroscopy 
M17 cells (ATCC, VA, USA, # CRL-2267) were harvested, and lysed 
with 1 X TBS. An IP was conducted as described in the manufacturer's 
user guide (Pierce™ NHS-Activated Magnetic Beads, MA, USA, # 
88826). Beads were conjugated with the eIF5AHypK50 antibody at a 
concentration of 0.5 μg of antibody/μg of beads. The hypusine-specific 
antibody, was manufactured by 21st Century Biochemicals, Inc., 
(Marlborough, MA, USA) and its specificity has been previously de-
scribed [26]. 1.5 mg/mll of soluble protein from antibody-conjugated 
beads sample. Sample with no antibody was used as control. Protein 
extracts were separated by SDS-PAGE. Coomassie-stained gel pieces 
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were excised from the regions of interest. Briefly, gel pieces were 
minced and de-stained before being reduced with dithiothreitol (DTT), 
alkylated with iodoacetamide (IAA), and finally digested with Trypsin/ 
Lys-C overnight at 37 °C. Peptides were extracted using 50/50 acet-
onitrile (ACN)/H2O/0.1% formic acid and dried in a vacuum con-
centrator. Peptides were resuspended in 98%H2O/2%ACN/0.1% 
formic acid for LC-MS/MS analysis. Experiments were performed in 
triplicate in two independent experiments. Peptides were separated 
using a 75 μm × 50 cm C18 reversed-phase-HPLC column (Thermo 
Fisher Scientific, MA, USA) on an Ultimate3000 UPLC system (Thermo 
Fisher Scientific, MA, USA) with a 60-min gradient (4–40% ACN with 
0.1% formic acid) and analyzed on a hybrid Quadrupole-Orbitrap in-
strument (Q Exactive Plus, Thermo Fisher Scientific, MA, USA). Orbi-
trap full MS survey scans were acquired at 60,000 resolution. The top 
10 most abundant ions were selected for MS/MS analysis in the linear 
ion trap. Raw data files were processed in MaxQuant (www.maxquant. 
org) and searched against the most current UniprotKB human protein 
sequence database. Search parameters included constant modification 
of cysteine by carbamidomethylation and the variable modification, 
methionine oxidation. Proteins were identified using the filtering cri-
teria of 1% protein and peptide false discovery rate. Proteins were 
ranked based on the number of unique peptides identified. 
2.6. Gene ontology analysis 
2.6.1. Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) was used to illustrate both net-
work interactions and enriched pathways associated with a data set of 
the top 50 proteins identified by mass spectrometry following co-im-
munoprecipitated with eIF5AHypK50. The network used the IPA Connect 
tool within the MyPathways feature to display both direct and indirect 
protein interactions annotated across human, mouse, and rat species. 
Databases from Ingenuity third party sources were applied for curating 
the displayed interactions with confidence levels ranging from “ex-
perimentally observed” to “moderately predicted”. Nodes within the 
network are distinguished by both region and color to show the top four 
associated pathways identified by the IPA Metabolomics Core Analysis 
tool. 
2.7. Enrichr analysis 
Enrichr software was used for Gene Ontology (GO) analysis on the 
full data set of 887 proteins identified from the co-IP procedure with 
MS. Enrichr GO libraries are constructed from multiple biological and 
biomedical online databases to compare overlap of a queried dataset 
with annotated gene sets representative of functional attributes. The top 
20 molecular functions and biological processes were ranked based on 
their relative combined scores; a comprehensive statistical parameter 
was used to associate annotated GO terms with the queried dataset. 
2.8. Surface sensing of translation (SUnSET) 
Changes in translation were evaluated with surface sensing of 
translation (SUnSET), which uses puromycin as a structural analog of 
aminoacyl tRNAs to prevent elongation after being incorporated into 
the nascent polypeptide chain. LAP-wtTDP-43 cells were grown on 6 
well plates (n = 3) and treated with GC7 as described in the Cell culture 
and treatment section. After 72 h, cells were treated with 1 μM pur-
omycin for 30 min at 37 °C, harvested and lysed with M-PER (Thermo 
Fisher Scientific, MA, USA, # 78501) containing protease inhibitor 
(Sigma Aldrich, MO, USA, # P8340), phosphatase inhibitor cocktails 2 
and 3 purchased from Sigma Aldrich, MO, USA, # P5726, and # P0044 
respectively, phenylmethylsulfonyl fluoride (0.1 M PMSF, Acros Or-
ganics, NJ, USA, # 215740050) and DNase (5 mg/mL, Alfa Aesar, MA, 
USA, # J62229) each at a 1:100 dilution. 20 μg of protein from each 
sample and standard was run on SDS-PAGE and Western blot. Standards 
were generated by mixing pooled puromycin-treated homogenates with 
pooled non-puromycin treated homogenates to desired percentages 
(100, 50, 25, 12.5, and 0% puromycin-treated). The membrane was 
probed puromycin (Millipore Sigma, MA, USA, # MABE343), eI-
F5AHypK50 (21st Century Biochemicals, MA, USA), and β-Actin (Abcam, 
Cambridge, UK, #ab13822). 
2.9. Cellular fractionation and Western blot 
LAP-wtTDP-43 were seeded on 15 cm cell culture dishes (n = 4), 
then treated as described in Cell culture and treatment section. Cells were 
washed and harvested with PBS and immediately followed by lysis with 
Sub-Cellular Fractionation Buffer (SFB) (250 mM sucrose, 10 mM KCl, 
20 mM HEPES pH 7.4, 1.5 mM MgCl2, 1 mM EDTA, and 1 mM EGTA) 
including protease inhibitor (Sigma Aldrich, MO, USA, # P8340), 
phosphatase inhibitor cocktail 2 and 3 purchased from Sigma Aldrich, 
MO, USA, # P5726, and # P0044 respectively, phenylmethylsulfonyl 
fluoride (0.1 M PMSF, Acros Organics, NJ, USA, # 215740050) and 
DNase (5 mg/mL, Alfa Aesar, MA, USA, # J62229) each at a 1:100 
dilution. Samples were agitated at 4 °C for 10 min and then centrifuged 
at 14,000 RPM at 4 °C for 10 min. The resulting supernatant was col-
lected as cytoplasmic fraction. The pellet was resuspended with SFB 
containing the inhibitors, agitated at 4 °C for 30 min followed by cen-
trifugation at 14,000 RPM at 4 °C for 10 min. The resulting supernatant 
was collected as the membrane fraction. The remaining pellet was re-
suspended in RIPA buffer (50 mM Tris HCl, 150 mM NaCl, 2 mM EDTA, 
0.1% SDS, 0.5% sodium deoxycholate, and 1% Triton x-100, pH 7.4), 
including the inhibitors, vortexed for 30 s, sonicated, and centrifuged at 
14,000 RPM at 4 °C for 10 min. This fraction denotes cellular nuclear 
proteins. Pellets from each fraction were washed 3 x with PBS to ensure 
complete removal of prior proteins. 10 μg of protein was analyzed by 
Western blot and probed for the following antibodies (Supplementary 
Table 4): TDP-43 (Abnova, Taiwan, # H00023435-M01), eIF5A 
(Abcam, MA, USA, # ab32443), eIF5AHyp-K50 (21st Century Biochem-
icals, MA, USA, customized), Lamin A/C (Cell Signaling, MA, USA, 
2032SeIF5AAcK47(Assay Biotech, CA, USA, # D12065), GAPDH (Pro-
teintech, IL, USA, # HRP-60004). Western blots were developed using 
Amersham imager 600 quick-start and analyzed using AlphaEaseFC 
software. 
2.10. Soluble and insoluble protein isolation 
LAP-wtTDP-43 cells were seeded in 6-well cell culture plates 
(n = 4) and treated similarly according to the Cell culture and treatment 
section then lysed for the soluble protein extraction using a RIPA buffer 
(50 mM Tris HCl, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 0.5% sodium 
deoxycholate, and 1% Triton x-100, pH 7.4) including the protease and 
phosphatase cocktail 2 and 3 inhibitors (Sigma Aldrich, MO, USA, # 
P5726, and # P0044 respectively), PMSF (Acros Organics, NJ, USA, # 
215740050), and DNase (Alfa Aesar, MA, USA, # J62229) each at a 
1:100 dilution. Samples were centrifuged at 14,000 RPM at 4 °C for 
10 min and the supernatant was stored as the RIPA soluble fraction. 
Pellet was rinsed in RIPA buffer, briefly centrifuged and the resulting 
pellet was then resuspended in urea buffer (7M urea, 2M Thiourea, 4% 
CHAPS, and 30mM Tris, pH 8.5), sonicated, and centrifuged at 
100,000 ×g at 4 °C for 30 min. The supernatant was collected and used 
as the urea soluble fraction. Immunoblot analysis was performed using 
5 μg of protein and probed with the following antibodies: TDP-43 (EMD 
Millipore, MA, USA, # MABN150), phospho TDP-43 (pS409/410-2) 
(Cosmo Bio Co, CA, USA, # TIP-PTD-P02), β-Actin (Sigma-Aldrich, MO, 
USA, # A5-441). 
2.11. Immunocytochemistry and confocal imaging 
LAP-wtTDP-43 cells were initially seeded for 24 h on fibronectin 
(2 μg/mlll, Sigma Aldrich, MO, USA, #F2006) coated coverslips 
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(Fisherbrand, PA, USA, # 22031145) and treated as described in the  
Cell culture and treatment section. Cells were fixed with 4% paraf-
ormaldehyde then permeabilized and blocked with 0.2% Triton x-100 
and 3% HI-FBS in PBS for 1 h. Cells were immunostained for 2 h using 
the following antibodies (Supplementary Table 4): TIAAI-1 (Santa Cruz 
Biotechnology, CA, USA, # sc-1751), TDP-43 (Abnova, CA, USA, # 
H00023435-M01), eIF5A (Abcam, MA, USA, # ab32443) and eI-
F5AHypK50 (21st Century Biochemicals, MA, USA, customized). Cells 
were incubated for 45 min at room temperature with corresponding 
Alexa Fluor secondary antibodies (Invitrogen, CA, USA). Slides were 
coverslipped with Vectashield Hardset Mounting Medium with DAPI 
(Vector Laboratories, CA, USA, # H1500) or Prolong Gold Antifade 
Mountant (Thermo Fisher Scientific, MA, USA, # P36934). In some 
instances, nuclei were stained using Hoechst 33342 (Thermo Fisher 
Scientific, MA, USA, # H3570). 
Images were obtained with an LSM880 Carl Zeiss Confocal 
Microscope using immersion oil with a 63× lens objective. Images for 
each fluorophore were obtained by sequential scanning where at least 
ten fields of interest were obtained with an average z-stack of eight 
frames per field. Images were merged and recovered using the ZEN 
microscope software. Co-localization analyses were carried out using 
Image J, and thresholding was kept constant across all pictures. Z-stack 
images taken for immunocytochemistry were acquired utilizing the 
Olympus Fluoview fv10i on the 63× water objective. Images were 
merged with Fv10i software. 
2.12. Statistical analysis 
Statistical analyses were performed using Student's t-test or one-way 
ANOVA followed by Tukey post-hoc means comparison test. The 
Western Blot analysis protein was normalized to GAPDH or actin ex-
pression. Values are represented as the standard error of the mean 
(SEM). P values were considered statistically significant when com-
pared to untreated control as followed: *p  <  0.05, **p  <  0.01 and 
***p  <  0.001. Statistical significance, when compared to SA treated 
sample, is denoted as #; p  <  0.05. Graphs were generated using 
GraphPad Prism 8.4 software (GraphPad Software, CA, USA). 
3. Results 
3.1. Protein-protein interactions of hypusinated eIF5A identified networks 
associated with neurodegenerative disorders 
Considering the regulatory role of eIF5AHypK50 in the translation of 
factors involved in stress response as well as SG assembly [27] and the 
emerging effect of TDP-43 accumulation in the cytoplasm and SGs 
[10,11,27–29] led us to explore the converging pathways between 
hypusinated eIF5A (eIF5AHypK50) and TDP-43 in relevant cellular 
models. We performed IP in human neuroblastoma M17 cells using an 
antibody against eIF5AHypK50 (21st Century Biochemicals, MA, USA). 
Mass spectrometry analysis identified a total of 886 proteins (data 
submitted to ProteomeExchange). Proteins were sorted by the intensity 
and unique peptides, and the top 50 proteins were used for bioinfor-
matic analysis using IPA. Analysis of the top 50 proteins identified three 
pathways that many of the identified proteins are involved in (network 
shown in Fig. 1A): RNA Post-Transcriptional Modification/RNA Da-
mage and Repair/Molecular Transport (light pink); Cellular Function 
and Maintenance/Molecular Transport/Cell Signaling Interactions 
(light blue) and Cell Death and Survival/Cellular Function and Main-
tenance (yellow). Additionally, IPA identified a significant representa-
tion of nuclear transport proteins that co-immunoprecipitated with eI-
F5AHypK50 (highlighted). The full list of functional associations of these 
pathways, based on IPA scoring parameters, is shown in Supplementary 
Table 1. 
Importantly within the proteome, the association between 
eIF5AHypK50 and TDP-43 was amongst the top seventh interactions 
identified in these cells, supporting the notion of a possible biological 
relevance between both proteins. Interestingly, several proteins asso-
ciated with neurological disorders were found amongst the eIF5AHypK50 
interactome. For example, we identified the microtubule-associated 
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Fig. 1. The IPA and functional analysis identified protein networks interacting with hypusinated eIF5A. A. Ingenuity Pathway Analysis was used to determine the 
canonical pathways associated with the 50 most abundant proteins enriched in the eIF5AHypK50 immunoprecipitation. The proteins are clustered based on the top 3 
associated canonical pathways; RNA Post-Transcriptional Modification, RNA Damage and Repair, and Molecular Transport (light pink); Cellular Function and 
Maintenance, Molecular Transport, and Cell Signaling Interactions (light blue); Cardiovascular Disease, Cell Death and Survival, Cellular Function and Maintenance 
(yellow). Full red and black lines represent the predicted relationship between proteins as identified by mass spectrometry analysis and curated IPA. Dashed and 
dotted lines represent experimentally observed relationships. Proteins examined in this study were bolded. B, C. The top 20 molecular functions and biological 
processes associated with all proteins identified by proteomics. The entire dataset (886 proteins) was analyzed using Enrichr software with the GO: database, and the 
top 20 most significant (p  <  0.05, combined scored) molecular functions and biological processes are shown. D. LAP-wtTDP-43 cells (+/- tetracycline, tet) and 
treated with 0.5 mM SA were immunoprecipitated with anti-TDP-43 or isotype IgG control antibodies; both IP and input lysate samples were probed with antibodies 
against TDP-43 and eIF5AHypK50. Arrow denotes the IgG band. 
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protein tau (MAPT), implicated in the neuropathology of various 
tauopathies and Alzheimer's disease [30], was associated with eI-
F5AHypK50. Other potential partners of eIF5AHypK50 included; syntaxin 
(STX1A), the determining factor for intelligence level in Williams 
Syndrome patients [31], Myelin basic protein (MBP), involved in de-
myelinating diseases such as multiple sclerosis [32], Synaptosomal as-
sociated Protein 25 kDa (SNAP-25) and Vesicle associated membrane 
proteins (VAMP), both associated with neurological disorders such as 
schizophrenia, attention-deficit/hyperactivity disorder and epilepsy 
[33]. 
Next, we employed Enrichr and Gene Ontology (GO) functional 
enrichment analysis on the full 886-protein interactome to annotate the 
biological relevance of the identified interactions (Fig. 1B, C). Not 
surprisingly, the “RNA-binding” and “rRNA Processing” were the most 
represented molecular functions and biological processes enriched 
within our data set. Computational ranking by the combined score in-
dicated RNA-binding to be 3.75–5-fold higher than all other molecular 
functions as identified by GO analysis (Fig. 1B, Supplemental Table 2). 
Also, SRP-dependent co-translational protein targeting to membrane, 
ncRNA processing, protein targeting to ER, and rRNA metabolic pro-
cesses were between 1.3 and 2-fold higher compared to the other ca-
tegories within the biological processes recognized (Fig. 1C, Supple-
mental Table 3). 
Considering our proteomics findings and the suggested functional 
interaction between eIF5AHypK50 and TDP-43 observed in Ba/F3 cell 
line [23], we aimed to investigate the biological function of such in-
teraction in further detail. We utilized wild type TDP-43 overexpressing 
tetracycline-regulatable isogenic HeLa cells (LAP-wtTDP-43 cells), 
(Fig. 1D). Sodium arsenite (SA) is used by many studies as a cellular 
stressor to achieve TDP-43 cytoplasmic localization and accumulation 
to SGs [10,34]. Therefore, cells were treated with 1 μg/ml tetracycline 
for 24 h, followed by 0.5 mM SA for 1 h, before IP using an antibody 
against human TDP-43 (Fig. 1D). Both input and IP fractions were 
analyzed by Western blot. The input fraction showed expression of both 
LAP-wtTDP-43 (80 kDa band) and endogenous wtTDP-43 (43 kDa 
band) upon tetracycline treatment (tet+), while only endogenous 
wtTDP-43 is present in the untreated cells (tet-, Fig. 1D). Conversely, 
eIF5AHypK50 was present in all cellular samples and was slightly in-
creased followed SA treatment. Interestingly, the IP fraction demon-
strated co-precipitation of both endogenous TDP-43 and LAP-TDP-43 
with eIF5AHypK50. Increased eIF5AHypK50 band intensity was observed in 
tet+/SA treated cells. The IgG isotype control did not yield any of the 
protein bands except the IgG band (arrow). Overall, the co-IP results 
confirmed the proteomics findings and suggested that the association 
between TDP-43 with eIF5AHypK50 might strengthen with stress and 
TDP-43 overexpression in this cellular model. 
3.2. eIF5AHypK50 colocalizes with TDP-43 in stress granules during arsenite- 
induced stress 
Data suggesting regulation of TDP-43 in the SG [35] prompted us to 
further investigate the role of eIF5AHypK50 in TDP-43 accumulation 
during stress. Cells treated as described above underwent im-
munocytochemical assay and were labeled against TDP-43 and T-Cell- 
Restricted Intracellular Antigen-1 (TIA-1), an RNA binding protein and 
SG marker shown to co-localize with TDP-43 [10,34]. Confocal imaging 
demonstrated TDP-43 integration into the SGs (Fig. 2A). Moreover, our 
analysis indicated that the accumulation of TDP-43 altered SG 
Fig. 2. Hypusinated eIF5A co-localizes with accumulated TDP-43 in stress granules during SA-induced cellular stress. A. Immunofluorescence images of wtTDP-43 
cells treated with 0.5 mM SA and stained for TDP- 43 (green), TIA-1 (red) and merged. B. Scatter plot representation of Image J analysis demonstrating the 
correlation between TDP-43 intensity and stress granule total area in the cytoplasm based on TIA-1 signal. Linear regression, r2 = 0.09, slope = − 0.64 ( ± 0.28), 
*p  <  0.05, n = 41 cells/experiment. C–P. Immunofluorescence images of wtTDP-43 cells immunofluorescence stained for TDP-43 (green), TIA-1 (purple), 
eIF5AHypK50 (red), Hoechst 33342 (blue), and the merged image. C–G. Untreated cells, H–L. Cells treated with 0.05 mM SA for 1 h and M–P. magnified images of TDP- 
43 positive stress granules in SA-induced cells. Q. Co-localization between eIF5AHypK50 and TDP-43 in the cytoplasmic TIA-1 positive granules, MOC analysis, n = 10 
cells/condition/experiment. Student t-test, ***p  <  0.001. 
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characteristics and high TIA-1 signal, and large SG size corresponded to 
cells with a low TDP-43 signal. In contrast, cells with high TDP-43 
signal intensity exhibited low TIA-1 signal intensity and smaller SG size 
(Fig. 2B, p = 0.03). The significant inverse correlation between the 
nuclear TDP-43 signal and the total area of TIA-1 positive SG are shown 
in Fig. 2B. 
The notion that TDP-43 and eIF5AHypK50 may interact physiologi-
cally and accumulate in SG led us to investigate the spatial relationship 
of TDP-43 and eIF5AHypK50 in SG and during SA-induced stress. LAP- 
wtTDP-43 cells were treated as before and immunolabeled with anti-
bodies against TDP-43, eIF5AHypK50, and TIA-1 (Fig. 2C-P). As expected, 
treatment with SA induced the formation of TIA-1 positive SGs (I and N) 
resulting in the mislocalization of TDP-43 into the cytoplasm and ac-
cumulation into SG (C, H, and M). Interestingly, stress prompted hy-
pusination of cytoplasmic eIF5A (E and J). We also observed increased 
co-localization of TDP-43 and eIF5AHypK50 in TIA-1 positive SGs during 
stress (M-P), which was further confirmed by Manders overlaping 
coefficient (MOC) analysis (Fig. 2Q, ***p  <  0.001). 
3.3. Reduction of hypusination prevents eIF5A binding with TDP-43 in 
stress granules 
Induced TDP43-eIF5AHypK50 co-localization in SGs during stress and 
the canonical role of eIF5A in SG assembly led us to hypothesize that 
eIF5A regulates accumulation of TDP-43 in SGs in a hypusine-depen-
dent manner. To explore this plausible pathway, we utilized the deox-
yhypusine synthase inhibitor, N1-guanyl-1, 7-diaminoheptane (GC7, 
IC50, 17 nM) [20], as it was previously reported to significantly reduce 
hypusination and SG assembly [27]. LAP-wtTDP-43 cells treated with 
30 μM GC7 for 72 h and followed by treatment with 0.5 mM SA for 1 h. 
Cells were stained against TDP-43, eIF5AHypK50 and TIA-1 (Fig. 3A, B- 
U). Per our previous findings, SA induced TDP-43 mislocalization to the 
cytoplasm and in TIA-1 positive SGs (Fig. 3G, H). Additionally, im-
munocytochemistry images showed that GC7 treatment reduced hy-
pusination levels in cells (Fig. 3N, S). Image J stain intensity analysis 
revealed that GC7 significantly decreased hypusination in both SA- 
treated and untreated cells (Fig. 3V, *p  <  0.05, #p  <  0.05 compared 
to the SA treated sample). Similarly, MOC analysis determined sig-
nificant co-localization between TDP-43 and eIF5AHypK50 in SGs, which 
was reduced following GC7 treatment (Fig. 3W, *p  <  0.05, #p  <  0.05 
compared to the SA treated sample). Additionally, we demonstrated 
that neither SA nor GC7 treatment reduced the cellular viability of LAP- 
Fig. 3. Reduction of hypusination decreased TDP-43 accumulation and co-localization with eIF5AHypK50 during cellular stress. A. HeLa treatment paradigm flow-
chart. B–U. Immunolabeled image of LAP wtTDP-43 (tet +) cells stained for TDP-43 (green), TIA-1 (purple), eIF5AHypK50 (red), Hoechst 33342 (blue), and the 
merged images. B–F. Untreated and G–K. treated cells with 0.5 mM SA, L.–P. or 30 μM GC7, and Q.–U. 30 μM GC7 followed by 0.5 mM SA. V. Levels of eIF5AHypK50 in 
the cell was determined by ImageJ analysis. W. Co-localization of TDP-43 with eIF5AHypK50 in TIA-1 positive regions in the cytoplasm was determined by MOC 
analysis. X. Cellular viability in treated HeLa cells was determined by the fluorescence intensity of AlamarBlue assay. Statistical analysis was performed by one-way 
ANOVA followed by Tukey post-hoc test (n = 10 cells/condition, each experiment was repeated three times), * p  <  0.05. # denotes statistical significance 
(p  <  0.05) compared to the SA treated sample. Immunolabeled images of tet-induced LAP wtTDP-43 cells following SA-induced stress and stained for i. TIA-1 (red), 
ii. DAPI (blue), and the iii. merged image. n = 82–98 cells/treatment *p  <  0.05. 
Table 1 
Stress granule properties.     
Measures SA  ±  SEM SA/GC7  ±  SEM  
# of SG per cell 61.68  ±  5.48 43.92  ±  4.79* 
Average SG size 70.06  ±  10.30 46.59  ±  5.19* 
Average SG density 2.43  ±  0.28 1.59  ±  0.25* 
P values were considered statistically significant compared to SA group as 
followed: *p < 0.05. Student t-test  
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wtTDP-43 HeLa cells, as measured by Alamar Blue cell viability assay 
(Fig. 3X). 
Next, we analyzed the impact of GC7 treatment on SG character-
istics, as identified by the positivity for TIA-1 expression (Fig. 3i-iii). 
The number of SGs, size, and density was analyzed (n = 82–98 cells per 
treatment). Indeed, cells treated with GC7/SA significantly decreased 
the number of SGs, the average granule size, and density in comparison 
to SA treated cells (Table 1, *p  <  0.05). 
3.4. Reduction of eIF5A hypusination does not affect global protein 
synthesis 
Although eIF5A is intimately involved in eukaryotic cell prolifera-
tion, the true physiological function of eIF5A has yet to be elucidated. 
For example, studies in S. cerevisiae mutant strain observed that the 
depletion of eIF5A generated only a relatively small inhibition of pro-
tein synthesis [36], while the polysome profiles of S. cerevisiae tem-
perature-sensitive mutants provided evidence that eIF5A distinctly ef-
fects translation elongation [17]. To investigate whether the observed 
changes in TDP-43 levels are a direct or indirect consequence of re-
duced “de novo” protein synthesis, we performed surface sensing of 
translation (SUnSET) assay as previously published [37]. In this assay, 
treatment with puromycin is incorporated into the nascent protein, 
hence allowing oversight onto the protein synthesis levels. Tet-induced 
LAP-wtTDP-43 cells were treated with 30 μM GC7 for 72 h, then with 
1 μM puromycin for 30 min at 37 °C. Immunoblot assay was performed 
and probed with antibodies against puromycin and eIF5AHypK50 
(Fig. 4A). Puromycin incorporation was standardized against standard 
samples. As expected, GC7 treatment significantly reduced levels of 
hypusination in treated cells (Fig. 4B, **p  <  0.01, ***p  <  0.001). 
However, GC7 treatment did not alter puromycin levels compared to 
standards and controls (Fig. 4C). We, therefore, determined that re-
duction in hypusine levels via GC7 did not affect overall protein 
synthesis in this cellular model. 
3.5. Decreased cytoplasmic TDP-43 levels following reduction of 
eIF5AHypK50 
Next, we aimed to investigate the effects of reduced hypusination on 
the cytoplasmic localization of TDP-43. Following our experimental 
paradigm, cells were fractionated in cytoplasmic and nuclear protein 
pool and analyzed by immunoblot (Fig. 5A). Treatment with GC7 sig-
nificantly reduced eIF5AHypK50, while inversely increasing levels of eI-
F5AAcK47 in the cytoplasmic fraction (Fig. 5B, *p  <  0.05, **p  <  0.01, 
***p  <  0.001, #p  <  0.05 compared to the SA treated sample). As 
acetylation of K47 within the “hypusine loop” represents another post- 
translational modification of eIF5A and competes with the ability to 
convert K50 to hypusine [38], our data confirm the inverse relationship 
of both post- translational modifications. 
Importantly, cytoplasmic to the nuclear ratio of LAP-TDP-43 and 
endogenous TDP-43 (eTDP-43) revealed a significant increase of TDP- 
43 levels in the cytoplasm of SA treated cells compared to the control 
sample (Fig. 5C, *p  <  0.05, ***p  <  0.001). Cells treated with GC7 
alone demonstrated a slight reduction in TDP-43 cytoplasmic levels, 
however, stressed cells treated with GC7 significantly reduced cyto-
plasmic TDP-43 accumulation. We further found that this was followed 
by induced nuclear levels of both LAP- and endogenous TDP-43 
(Fig. 5C, #p  <  0.05 compared to the SA treated sample). These find-
ings suggest that reduction in hypusine levels regulates cytoplasmic 
TDP-43 accumulation by possibly rescuing the nuclear re-entry of TDP- 
43. 
3.6. Hypusine dependent interactions of eIF5A with nuclear transport 
machinery proteins 
To further investigate the nucleocytoplasmic shuttling of TDP-43 we 
returned to the mass spectrometry data and protein cluster analysis. 
Interestingly, within the IPA analysis, we identified a cluster of nuclear 
transport proteins that co-IP with eIF5AHypK50; that included KPNA1 
(importin subunit α5), KPNA2 (importin subunit α1), KPNB1 (importin 
subunit β), and RanGTP (Fig. 6A). These proteins are part of the nuclear 
importin complex responsible for binding to cytoplasmic cargo via 
nuclear localization signals (NLS) and translocation through the nuclear 
pore complex (NPC) [39,40]. RanGTP is essential for the nuclear 
transport of cargo protein via the NPC into the nuclear interior [41–43]. 
To determine whether modifications of the hypusine levels affect nu-
clear transport machinery, we investigated importin's cytoplasmic lo-
calization and expression by immunoblot assay (Fig. 6B). Analysis of 
the cytoplasmic fraction indicated that stress alone was insufficient to 
modify the cytoplasmic levels of the NPC proteins. However, GC7 
treatment in SA-stressed cells significantly reduced KPNA1, KPNB1, 
RanGTP levels (Fig. 6C, *p  <  0.05) but not KPNA2 (p = 0.07). Al-
together, our data demonstrate that reduced hypusination alters cyto-
plasmic importin levels and possibly facilitated their nuclear gradient. 
3.7. Reduced eIF5A hypusination decreases insoluble TDP-43 levels 
following cellular stress 
A hallmark of pathology is the cytoplasmic presence of hyper- 
phosphorylated and aggregated TDP-43 [44]. To determine whether 
hypusination affected TDP-43 phosphorylation and aggregation, we 
isolated RIPA and Urea-soluble cellular fractions of treated tet-induced 
LAP-wtTDP-43 cells (Fig. 7A). Immunoblots from each fraction were 
probed with antibodies against total and phosphorylated TDP-43 at 
serine 409/410 epitope (pTDP-43, Fig. 7B). We observed an immediate 


























































Fig. 4. Nascent protein synthesis is not impaired following a reduction in hy-
pusination levels. SUnSET assay measuring puromycin incorporation into pro-
teins during translation in LAP wtTDP-43 (tet +) cells treated with 30 μM GC7. 
A. Western blot of puromycin-tagged proteins, cellular standards, and 
eIF5AHypK50 levels are shown. B. Quantification of hypusine levels in cells 
following puromycin treatment. C. Levels of puromycin incorporation during 
protein synthesis. Cellular extracts with known protein amounts were used as 
standards for quantification purposes (100, 50, 25, 12.5, and 0% puromycin- 
treated). Actin is used as a loading control. Statistical analysis was performed 
by one-way ANOVA followed by Tukey post-hoc test. ** p  <  0.01, *** 
p  <  0.001, ns. not significant. 
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Fig. 5. Reduction of hypusination prevents cytoplasmic mislocalization of TDP-43. A. Immunoblot of the subcellular fractions of LAP wtTDP-43 cells following 
treatment. The cytoplasmic and nuclear fractions were probed for endogenous TDP-43, LAP-TDP-43, hypusinated and acetylated eIF5A. B. Densitometry quantifi-
cation of cytoplasmic eIF5AHypK50 and eIF5AAcK47 levels normalized to actin. C. Cytoplasmic to the nuclear ratio of endogenous and LAP-TDP-43 levels following 
treatment. Statistical analysis was determined by one-way ANOVA followed by Tukey post-hoc test; *p  <  0.05, **p  <  0.01, ***p  <  0.001, or ns. not significant, # 
p  <  0.05, when compared to SA treated sample. 
Fig. 6. A. Mass spectrometry and IPA analysis identified a cluster of nuclear transport proteins interacting with eIF5AHypK50. B. Immunoblot of the cytoplasmic levels 
for RAN, KPNA1, and 2 and KPNB1 proteins. C. Densitometry quantification of cytoplasmic levels of RAN, KPNA1, and 2 and KPNB1 normalized to actin. Lamin A/C, 
GAPDH, or actin were used as loading controls. Statistical analysis was determined by one-way ANOVA followed by Tukey post-hoc test; *p  <  0.05. 
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43 (eTDP-43) after 1 h of SA treatment compared to the untreated 
sample (Fig. 7C). GC7 alone did not affect the solubility of the protein 
compared to the untreated sample. However, stressed cells treated with 
GC7 significantly reduced insoluble TDP-43 and recovered the levels of 
soluble LAP-TDP-43 and eTDP-43 levels compared to SA treated cells 
(p  <  0.05, # compared to SA). 
Next, we analyzed levels of phosphorylated S409/410 TDP-43 and 
revealed that stress significantly induced phosphorylation and in-
solubility of both LAP-pTDP-43 and e-pTDP-43 when compared to the 
untreated cells (Fig. 7D, *p  <  0.05 and **p  <  0.01, respectively). 
GC7-treated cells only slightly reduced insoluble LAP-pTDP-43 levels. 
Importantly, following SA stress, GC7 treatment significantly reduced 
the insoluble pTDP-43 levels and recovered the soluble LAP-pTDP-43 
and e-pTDP-43 protein levels (**p  <  0.01, compared to the untreated 
sample, p  <  0.05, # compared to SA). 
These findings together provide first-time evidence for a direct role 
of eIF5AHypK50 in TDP-43 biology, where pharmacological reduction of 
hypusination reduces phosphorylated and insoluble TDP-43 levels. 
3.8. Site-directed mutagenesis of the hypusine loop regulates TDP-43 
phosphorylation levels 
To further investigate the role of the hypusine loop modifications in 
TDP-43 pathology, we performed site-directed mutagenesis. The 
pCEFL-GFP eIF5A plasmid backbone was modified from lysine to ar-
ginine at lysine 47 and 50 of the hypusine loop (GFP-eIF5AK50R and 
GFP-eIF5AK47R, Fig. 8A). Both plasmids were overexpressed in the 
human Hek293T cell line. Untreated cells and cells transfected with 
non-mutated eIF5A plasmid (GFP-eIF5A) were included as controls. 
Cells were also co-transfected with two additional plasmids, DHS and 
DOHH (Flag-DOHH/DHS), as it has been suggested that DHS and 
DOHH activity is needed for the hypusination of exogenous eIF5A [45]. 
As expected, eIF5A protein did not undergo hypusination or acetylation 
in cells transfected with GFP-eIF5AK50R and GFP-eIF5AK47R, respec-
tively (lane 7 & 8 vs. lane 9 & 10) (Fig. 8B). We also found that co- 
expression of eIF5A with DHS/DOHH was not required for exogenous 
or endogenous eIF5A hypusination (lanes 3 & 4 vs. 5 & 6) as similar 
hypusination levels were maintained following each condition 
(Fig. 8C). In addition, eIF5A alone or in co-expression with DHS/DOHH 
significantly induced total TDP-43 levels, while mutations did not sig-
nificantly affect such levels (Fig. 8B and D). However, the expression of 
GFP-eIF5AK50R (loss of hypusination) led to dramatic reductions in le-
vels of phosphorylated S409/410 TDP-43 compared to cells expressing 
induced hypusination constructs (lanes 3–8) and untreated cells (lane 1 
& 2, Fig. 8B and D). Conversely, pS409/410 TDP-43 levels were sig-
nificantly increased in cells transfected with either GFP-eIF5A, GFP- 
eIF5A/Flag-DHS/DOHH or GFP-eIF5AK47R (loss of acetylation, Fig. 8D). 
We found no changes in the expression levels of endogenous total and 
hypusinated eIF5A (Fig. 8B, C). Taken together, our data provide me-
chanistic evidence on the role of acetylation vs. hypusination in cyto-
plasmic accumulation of TDP-43. The dynamics of both acetylation and 
hypusination within the eIF5A hypusine loop might provide a novel 
entry-point for future therapeutic targets in TDP-43 proteinopathies. 
4. Discussion 
This study demonstrates a key role of hypusinated eIF5A in TDP-43 
pathology in an SA-induced stress cellular model. We found that 
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Fig. 7. -Reduced eIF5A hypusination decreases insoluble TDP-43 levels following cellular stress. A. Description of the RIPA and Urea fractionation method used to 
separate soluble and insoluble proteins from treated LAPwtTDP-43 (tet+) cells. B. Western blot determined total and phosphorylated Ser409/410 TDP-43 levels in 
RIPA and Urea-treated fractions. C. Densitometry quantifications of soluble to insoluble protein ratio. Actin was used as a loading control for the RIPA soluble 
fraction. Statistical analysis was determined by one-way ANOVA followed by Tukey post-hoc test, # denotes statistical significance (p  <  0.05) compared to the SA 
treated sample, *p  <  0.05, **p  <  0.01, # denotes comparisons to the SA treated sample. 
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reduction of hypusination alleviates TDP-43 cytoplasmic mislocaliza-
tion and the accumulation into SGs. Our proteomics and functional data 
demonstrated a physiological interaction between eIF5AHypK50 and 
TDP-43, which was exacerbated during induced cellular stress and TDP- 
43 overexpression. We also report that reduction of hypusination by 
GC7 or mutagenesis led to decreased cytoplasmic total TDP-43 levels, 
phosphorylated and insoluble TDP-43 in two separate cellular models. 
Interestingly, we show that GC7 significantly reduced co-localization 
between TDP-43 and eIF5AHypK50 both in the cytoplasm and SGs fol-
lowing SA-induced cellular stress. Importantly, we observed that re-
duced hypusine levels neither affected the general “de novo” protein 
synthesis nor cellular growth of HeLa cells. In agreement with our 
findings, others have shown that HeLa cells treated with eIF5A-shRNA 
displayed a growth curve similar to that of the non-transduced cells up 
to 72 h. Measurements of total protein synthesis by pulse labeling with 
[3H]leucine revealed relatively small inhibition (< 20%) and authors 
concluded there is no global inhibition of protein synthesis when eIF5A 
is depleted [36]. 
Using mass spectrometry and protein interactome analysis, we 
identified key associated functional networks between eIF5AHypK50 and 
proteins within the “RNA-binding” and “rRNA Processing” biological 
and molecular processes. Interestingly, TDP-43 protein was one of the 
RNA-binding proteins (RBPs) that was highly scored in our data-set and 
implicated in the neuropathology of the ALS-FTD-AD spectrum of de-
mentias [4,44,46]. Several studies have demonstrated that top RBPs, 
such as TDP-43, TIA-1, and FUS, harbor a canonical RNA recognition 
motif (RRM) and low-complexity domains critical for the formation of 
pathological aggregates in cytoplasm and SGs in brain. [47–49]. These 
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Fig. 8. Site-directed mutagenesis of eIF5A at lysine (K)50 and K47 modulate the phosphorylation of TDP-43. A. Site-directed mutagenesis of wild type GFP-eIF5A 
yield the substitution mutants at K47R and K50R (red circles). The chromatogram was obtained by sequencing the antisense strand of pCEFLGFP-eIF5A plasmid using 
primer sp6. Corresponding mutated sequences are highlighted with the red circle. B. Hek293T cell transfection was performed as described and the cytoplasmic 
fraction was analyzed by Western blot with antibodies against eIF5AHypK50 and eIF5AAcK47, total eIF5A, Flag, total TDP-43, and pS409/410 TDP-43. C, D. 
Densitometry quantifications of cytoplasmic levels of each protein. GAPDH was used as a loading control. Statistical analysis was performed by one-way ANOVA with 
Tukey post-hoc test. *p  <  0.05, **p  <  0.01 ***p  <  0.001. 
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membrane-less organelles contain a plethora of translation elongation 
initiation factors (eIF2, 3, 4, and 5) [50], small ribosomal subunits [51], 
and RBPs [52] shown to regulate the accumulation of numerous pro-
teins and mRNA in SG. For instance, TDP-43 co-localization with SGs- 
specific RBPs TIA-1, eIF3 and PABP (polyadenylate-binding protein) 
was observed in both ALS and FTD brain [8–10,29,53] and in animal 
models [10,12]. In agreement with these studies, we reported co-loca-
lization of eIF5AHypK50 with TDP-43 in TIA-1 positive SGs upon cellular 
stress, an effect that was significantly reduced by GC7 treatment (Figs. 2 
and 3). Interestingly, hypusinated eIF5A promotes SG assembly in an 
arsenite-induced cellular model and was efficiently reduced by GC7 
treatment [27]. Similarly, we report here that reduced hypusination via 
GC7 significantly decreased SG number and density within the cell. 
More so, we demonstrated that GC7 treatment significantly decreased 
TDP-43 accumulation within the SG. This is in line with several studies 
raising the possibility of SG representing sites of early protein seeding 
and TDP-43 cytoplasmic aggregation [11]. To this point, we provided 
evidence that GC7 treatment significantly decreased cytoplasmic TDP- 
43 phosphorylation and aggregation, as measured in urea-soluble 
fraction (Fig. 6). However, our findings did not determine if SGs are a 
Fig. 9. Hypothetical model of the stress-induced nucleocytoplasmic transport and accumulation of TDP-43 via eIF5AHypK50. In the cytoplasm, the interactions 
between cytoplasmic eIF5AHypK50 and TDP-43 strengthen, leading to the TDP-43 cytoplasmic retention and accumulation. We suggest that eIF5AHypK50 governs the 
accumulation of TDP-43 into TIA-1 positive stress granule, solidifying the role of eIF5AHypK50 as a regulator of the stress granule formation during cellular stress. 
Additionally, we find that eIF5AHypK50 is interacting with importins KPNA1/A2 and KPNB1 in the cytoplasm. We hypothesize that induced hypusination during stress 
promotes complex formations, leading to failed TDP-43 nuclear import and ultimately TDP-43 cytoplasmic sequestration. Subverting eIF5AHypK50 with novel 
pharmacological or genetic tools reduces cytoplasmic insoluble TDP-43 burden by recovering nucleocytoplasmic shuttling of TDP-43 as well as stabilize the stress 
granule dynamic. 
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contributing source of aggregated TDP-43 and require further in-
vestigation. 
Studies suggest that the charged moiety of the exposed “hypusine loop” 
region, spanning Ser46-Ala54 (SK47TGK50HGHA), is important for eIF5A 
activity [54]. Indeed, we demonstrated that mutation of K47 and K50 to 
arginine (R) completely abolishes lysine acetylation and hypusination, re-
spectively, which replicates the original findings from Park and colleagues 
[22,38,45]. More importantly, for the first time, we provide evidence that 
expression of eIF5AK50R mutant vastly reduced levels of total and pS409/ 
410 TDP-43 in cells. Conversely, we show expression of eIF5AK47R main-
tained eIF5A hypusination and induced pTDP-43 in these cells (Fig. 4). 
Altogether, our data suggest that eIF5A hypusine vs. acetyl levels regulates 
TDP-43 cytoplasmic accumulation and aggregation. We also provide evi-
dence that this regulatory pathway can be targeted by pharmacological and 
mutagenesis approaches against the hypusine loop moiety. 
Notably, eIF5A hypusination has been proposed to regulate mRNA 
translation [55,56], nucleocytoplasmic shuttling of retroviral Rev., Rex 
RNA transport factors, and iNos mRNA processing [16,18]. For in-
stance, eIF5A is involved in the CRM1/exportin cargo transport from 
the nucleus to the cytoplasm at the NPC [57]. Albeit our study did not 
focus on the translational regulation or the nucleocytoplasmic shuttling 
of eIF5AHypK50, both proteomic enrichment data and biochemical ana-
lyzes provided evidence that NPC proteins, specifically importins 
KPNA1/2 KPNB1 and RanGTP were binding partners of eIF5AHypK50 
and were regulated by the hypusine levels. Indeed, we show that GC7 
reduced KPNA1/2, B1, and RanGTP cytoplasmic expression levels, in-
dependent of SA-induced cellular stress (Figs. 1 and 4), which increased 
nuclear TDP-43 levels. The concentration of RanGTP in the nucleus and 
RanGDP in the cytosol forms a gradient harnessed by importins and 
exportins to provide nucleocytoplasmic transport [41–43]. This is of 
particular relevance since perturbed nucleocytoplasmic shuttling was 
recently found in diseases associated with mutations in the nuclear 
localization signals (NLSs) of FUS and in Heterogeneous nuclear ribo-
nucleoprotein A1 (hnRNPA1) in ALS [47,58,59] and in chromosome 9 
open reading frame 7 (C9ORF72) in both ALS and FTD cases [60–62]. 
Indeed, one study identified several NPC components within detergent- 
insoluble TDP-43 aggregates by proximity-dependent biotin identifi-
cation (BioID) assay [63]. Others have recently demonstrated that cy-
toplasmic TDP-43 droplets recruit importin-alpha and Nup62, leading 
to mislocalization of RanGap1 and impaired nucleocytoplasmic trans-
port, TDP-43 loss of function, and cell death [64]. Altogether, these 
studies strongly implicate pathology and transient stress to induce NPC 
dysfunction as a common mechanism for TDP-43 proteinopathy. 
Here, we report mechanistic evidence that hypusination levels de-
termine the interactions of eIF5A with TDP-43 and KPNA/B proteins. 
Based on our findings, we suggest that cytoplasmic interactions be-
tween TDP-43 and eIF5AHypK50 are strengthened by cellular stress 
leading to the TDP-43 cytoplasmic retention and accumulation (Fig. 9). 
We also posit that eIF5AHypK50 governs the accumulation of TDP-43 into 
TIA-1 positive SGs, solidifying the role of eIF5AHypK50 as a regulator of 
the SG formation. Additionally, as the interactions between eIF5AHypK50 
and KPNA1/A2 and KPNB1 are dependent on the hypusine levels, we 
propose that induced hypusination promotes eIF5AHypK50 interactions 
with KPNA1/2 and KPNB1, failing a proper TDP-43 nuclear import and 
ultimately contributing to TDP-43 cytoplasmic sequestration. 
5. Conclusion 
We show here that approaches against hypusination reduced in-
soluble TDP-43 levels by recovering nucleocytoplasmic shuttling of 
TDP-43 as well as stabilizing the SG dynamic. This study provides 
evidence on the role of the eIF5A hypusine loop as a unique target in 
common mechanisms of TDP-43 proteinopathies. Understanding the 
eIF5AhypK50 governance of TDP-43 nucleocytoplasmic transport in dis-
ease-relevant models is crucial for future therapeutic approaches of 
TDP-43 pathogenesis. 
Supplementary data to this article can be found online at https:// 
doi.org/10.1016/j.bbadis.2020.165939. 
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